Neogen vs Twist Bioscience: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Neogen Corporation (NEOG)

Q3 202624 Jul – 7 Oct 2026

▲3▼1

Neogen's growth bets meet an FDA safety blow

Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.
The earnings beat and guidance are the core reason the stock jumped and set the period's direction.
R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.
This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.
FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.
It is the main negative force this period and a real counterweight to the upbeat earnings news.
Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.
The fresh guidance increase is the newest positive catalyst and confirms the growth trend.

August 202624 Jul – 7 Oct 2026

▲3▼1

Neogen's growth bets meet an FDA safety blow

Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.
The earnings beat and guidance are the core reason the stock jumped and set the period's direction.
R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.
This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.
FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.
It is the main negative force this period and a real counterweight to the upbeat earnings news.
Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.
The fresh guidance increase is the newest positive catalyst and confirms the growth trend.

Latest24 Jul – 7 Oct 2026

▲3▼1

Neogen's growth bets meet an FDA safety blow

Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.
The earnings beat and guidance are the core reason the stock jumped and set the period's direction.
R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.
This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.
FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.
It is the main negative force this period and a real counterweight to the upbeat earnings news.
Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.
The fresh guidance increase is the newest positive catalyst and confirms the growth trend.

Twist Bioscience Corp (TWST)

Q3 202619 Jun – 19 Aug 2026

▲4

Twist's AI-driven DNA demand and raised guidance fuel strong gains

AI genomic database deals drive new business Tech firms building genomic databases for AI models are outsourcing lab work to Twist, creating a new revenue stream. This growing demand for synthetic DNA pushes TWST's price up because it opens a large, fast-growing market beyond traditional biotech customers.
This is a new growth driver that directly boosts revenue expectations and investor enthusiasm.
Strong results and reaffirmed breakeven guidance Twist reported results well ahead of expectations and reaffirmed it will reach adjusted EBITDA breakeven in fiscal Q4 2026. This pushes the stock up because it shows the company is moving toward profitability while still growing quickly.
This is a new financial milestone that reassures investors about the company's path to profitability.
Raised fiscal 2026 revenue guidance to $456–$457 million Twist raised its full-year revenue outlook after a 23% jump in quarterly revenue, with DNA Synthesis and Protein Solutions up 39%. This lifts the stock because it signals stronger-than-expected demand and management confidence in future growth.
This is a new, concrete upward revision that directly affects valuation and investor confidence.
Biotech sector rally and Anthropic selection Biotech stocks hit post-pandemic highs after a major mRNA cancer trial win, and Anthropic chose Twist as an independent evaluator. This boosts TWST because sector-wide enthusiasm and a high-profile AI partnership increase demand for its services.
This is a new sector catalyst and partnership that raises Twist's visibility and demand outlook.

July 202619 Jun – 19 Aug 2026

▲4

Twist's AI-driven DNA demand and raised guidance fuel strong gains

AI genomic database deals drive new business Tech firms building genomic databases for AI models are outsourcing lab work to Twist, creating a new revenue stream. This growing demand for synthetic DNA pushes TWST's price up because it opens a large, fast-growing market beyond traditional biotech customers.
This is a new growth driver that directly boosts revenue expectations and investor enthusiasm.
Strong results and reaffirmed breakeven guidance Twist reported results well ahead of expectations and reaffirmed it will reach adjusted EBITDA breakeven in fiscal Q4 2026. This pushes the stock up because it shows the company is moving toward profitability while still growing quickly.
This is a new financial milestone that reassures investors about the company's path to profitability.
Raised fiscal 2026 revenue guidance to $456–$457 million Twist raised its full-year revenue outlook after a 23% jump in quarterly revenue, with DNA Synthesis and Protein Solutions up 39%. This lifts the stock because it signals stronger-than-expected demand and management confidence in future growth.
This is a new, concrete upward revision that directly affects valuation and investor confidence.
Biotech sector rally and Anthropic selection Biotech stocks hit post-pandemic highs after a major mRNA cancer trial win, and Anthropic chose Twist as an independent evaluator. This boosts TWST because sector-wide enthusiasm and a high-profile AI partnership increase demand for its services.
This is a new sector catalyst and partnership that raises Twist's visibility and demand outlook.

Latest19 Jun – 19 Aug 2026

▲4

Twist's AI-driven DNA demand and raised guidance fuel strong gains

AI genomic database deals drive new business Tech firms building genomic databases for AI models are outsourcing lab work to Twist, creating a new revenue stream. This growing demand for synthetic DNA pushes TWST's price up because it opens a large, fast-growing market beyond traditional biotech customers.
This is a new growth driver that directly boosts revenue expectations and investor enthusiasm.
Strong results and reaffirmed breakeven guidance Twist reported results well ahead of expectations and reaffirmed it will reach adjusted EBITDA breakeven in fiscal Q4 2026. This pushes the stock up because it shows the company is moving toward profitability while still growing quickly.
This is a new financial milestone that reassures investors about the company's path to profitability.
Raised fiscal 2026 revenue guidance to $456–$457 million Twist raised its full-year revenue outlook after a 23% jump in quarterly revenue, with DNA Synthesis and Protein Solutions up 39%. This lifts the stock because it signals stronger-than-expected demand and management confidence in future growth.
This is a new, concrete upward revision that directly affects valuation and investor confidence.
Biotech sector rally and Anthropic selection Biotech stocks hit post-pandemic highs after a major mRNA cancer trial win, and Anthropic chose Twist as an independent evaluator. This boosts TWST because sector-wide enthusiasm and a high-profile AI partnership increase demand for its services.
This is a new sector catalyst and partnership that raises Twist's visibility and demand outlook.